Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.

Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, Bhola PD, Ryan J, Guerriero JL, Montero J, Liang FJ, Cherniack AD, Piccioni F, Matulonis UA, Bowtell DDL, Sarosiek KA, Letai A, Garraway LA, Johannessen CM, Meyerson M.

Mol Cancer Res. 2019 Aug 28. doi: 10.1158/1541-7786.MCR-18-1243. [Epub ahead of print]

PMID:
31462500
2.

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, Johannessen CM, Lane AA.

J Clin Invest. 2019 Aug 22. pii: 128571. doi: 10.1172/JCI128571. [Epub ahead of print]

3.

Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.

Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, Heaton T, Cifani P, Dome JS, Gadd S, Perlman E, Mullen E, Steen H, Kentsis A.

JCI Insight. 2019 Aug 8;4(15). pii: 127098. doi: 10.1172/jci.insight.127098. eCollection 2019 Aug 8.

4.

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.

Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML.

Nat Commun. 2019 Aug 2;10(1):3485. doi: 10.1038/s41467-019-11371-x.

5.

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.

Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, Scheffold A, Villalobos-Ortiz M, Boldrin E, Zinngrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, Kestler HA, Bourquin JP, Stilgenbauer S, Letai A, Debatin KM, Meyer LH.

Cell Death Dis. 2019 Jul 29;10(8):571. doi: 10.1038/s41419-019-1801-0.

6.

BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics.

Villalobos-Ortiz M, Ryan J, Mashaka TN, Opferman JT, Letai A.

Cell Death Differ. 2019 Jul 22. doi: 10.1038/s41418-019-0391-9. [Epub ahead of print]

PMID:
31332296
7.

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL.

Blood. 2019 Jul 11;134(2):160-170. doi: 10.1182/blood.2019000789. Epub 2019 May 1.

PMID:
31043423
8.

MCL1 and DEDD Promote Urothelial Carcinoma Progression.

Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, Hahn WC.

Mol Cancer Res. 2019 Jun;17(6):1294-1304. doi: 10.1158/1541-7786.MCR-18-0963. Epub 2019 Feb 18.

PMID:
30777879
9.

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.

Singh R, Letai A, Sarosiek K.

Nat Rev Mol Cell Biol. 2019 Mar;20(3):175-193. doi: 10.1038/s41580-018-0089-8. Review.

PMID:
30655609
10.

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM.

Blood. 2019 Feb 7;133(6):566-575. doi: 10.1182/blood-2018-07-865527. Epub 2018 Nov 29.

PMID:
30498064
11.

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.

Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A.

J Exp Med. 2018 Dec 3;215(12):3094-3114. doi: 10.1084/jem.20180570. Epub 2018 Nov 7.

12.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A.

Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.

13.

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.

Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN, Chapuy B, Shipp MA.

Blood. 2019 Jan 3;133(1):70-80. doi: 10.1182/blood-2018-08-872465. Epub 2018 Oct 15.

PMID:
30322870
14.

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ.

JCI Insight. 2018 Oct 4;3(19). pii: 121438. doi: 10.1172/jci.insight.121438.

15.

BCL-2 inhibition in AML: an unexpected bonus?

Konopleva M, Letai A.

Blood. 2018 Sep 6;132(10):1007-1012. doi: 10.1182/blood-2018-03-828269. Epub 2018 Jul 23. Review.

16.

Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance.

Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, Andrews DW.

EMBO Rep. 2018 Sep;19(9). pii: e45235. doi: 10.15252/embr.201745235. Epub 2018 Jul 9.

17.

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.

Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Mar B, Mertins P, Fereshetian S, Krug K, Zhu H, Letai A, Carr SA, Doench J, Jaiswal S, Ebert BL.

Blood. 2018 Sep 13;132(11):1095-1105. doi: 10.1182/blood-2018-05-850339. Epub 2018 Jun 28.

18.

Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.

Taylor Ripley R, Surman DR, Diggs LP, Trepel JB, Lee MJ, Ryan J, Davis JL, Steinberg SM, Hernandez JM, Hoang C, Kenney CM, Bond CD, Kunst TF, Letai A, Schrump DS.

BMC Gastroenterol. 2018 Jun 22;18(1):94. doi: 10.1186/s12876-018-0823-x.

19.

Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.

20.

Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.

Letai A.

J Clin Oncol. 2018 Jul 1;36(19):1991-1993. doi: 10.1200/JCO.2018.78.2763. Epub 2018 May 22. No abstract available.

PMID:
29787358
21.

Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage.

Gutierrez-Martinez P, Hogdal L, Nagai M, Kruta M, Singh R, Sarosiek K, Nussenzweig A, Beerman I, Letai A, Rossi DJ.

Nat Cell Biol. 2018 Apr;20(4):413-421. doi: 10.1038/s41556-018-0054-y. Epub 2018 Mar 12.

22.

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.

Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, Bhola P, O'Donnell C, Spitzer B, Stutzke C, Lavallée VP, Hébert J, Krivtsov AV, Melnick A, Paietta EM, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A.

Cancer Discov. 2018 Apr;8(4):478-497. doi: 10.1158/2159-8290.CD-17-1271. Epub 2018 Feb 5.

23.

Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells.

Rezaei Araghi R, Bird GH, Ryan JA, Jenson JM, Godes M, Pritz JR, Grant RA, Letai A, Walensky LD, Keating AE.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E886-E895. doi: 10.1073/pnas.1712952115. Epub 2018 Jan 16.

24.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA.

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

PMID:
29339097
25.

ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors.

Terai H, Kitajima S, Potter DS, Matsui Y, Quiceno LG, Chen T, Kim TJ, Rusan M, Thai TC, Piccioni F, Donovan KA, Kwiatkowski N, Hinohara K, Wei G, Gray NS, Fischer ES, Wong KK, Shimamura T, Letai A, Hammerman PS, Barbie DA.

Cancer Res. 2018 Feb 15;78(4):1044-1057. doi: 10.1158/0008-5472.CAN-17-1904. Epub 2017 Dec 19.

26.

Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.

Lagares D, Santos A, Grasberger PE, Liu F, Probst CK, Rahimi RA, Sakai N, Kuehl T, Ryan J, Bhola P, Montero J, Kapoor M, Baron M, Varelas X, Tschumperlin DJ, Letai A, Tager AM.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaal3765. doi: 10.1126/scitranslmed.aal3765.

PMID:
29237758
27.

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, Konopleva M, Letai A.

Cancer Discov. 2017 Dec;7(12):1376-1393. doi: 10.1158/2159-8290.CD-17-0797. Epub 2017 Nov 16. Review.

28.

Why do BCL-2 inhibitors work and where should we use them in the clinic?

Montero J, Letai A.

Cell Death Differ. 2018 Jan;25(1):56-64. doi: 10.1038/cdd.2017.183. Epub 2017 Oct 27. Review.

29.

Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways.

Saito Y, Mochizuki Y, Ogahara I, Watanabe T, Hogdal L, Takagi S, Sato K, Kaneko A, Kajita H, Uchida N, Fukami T, Shultz LD, Taniguchi S, Ohara O, Letai AG, Ishikawa F.

Sci Transl Med. 2017 Oct 25;9(413). pii: eaao1214. doi: 10.1126/scitranslmed.aao1214.

30.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness.

Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP.

Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1.

31.

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.

Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, Clark PM, Cloughesy TF, Letai A, Nathanson DA.

Nat Med. 2017 Nov;23(11):1342-1351. doi: 10.1038/nm.4418. Epub 2017 Oct 9.

32.

Inhibition of USP10 induces degradation of oncogenic FLT3.

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ.

Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2.

33.

Functional precision cancer medicine-moving beyond pure genomics.

Letai A.

Nat Med. 2017 Sep 8;23(9):1028-1035. doi: 10.1038/nm.4389.

PMID:
28886003
34.

Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1.

Jenson JM, Ryan JA, Grant RA, Letai A, Keating AE.

Elife. 2017 Jun 8;6. pii: e25541. doi: 10.7554/eLife.25541.

35.

Synergistic interactions with PI3K inhibition that induce apoptosis.

Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, Letai A, Root DE, Langer RS, Gray N, Hahn WC.

Elife. 2017 May 31;6. pii: e24523. doi: 10.7554/eLife.24523.

36.

Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection.

Price AM, Dai J, Bazot Q, Patel L, Nikitin PA, Djavadian R, Winter PS, Salinas CA, Barry AP, Wood KC, Johannsen EC, Letai A, Allday MJ, Luftig MA.

Elife. 2017 Apr 20;6. pii: e22509. doi: 10.7554/eLife.22509.

37.

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.

Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A.

Nature. 2017 Mar 16;543(7645):428-432. doi: 10.1038/nature21409. Epub 2017 Mar 8.

PMID:
28273064
38.

Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis.

Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S.

Cancer Lett. 2017 Jun 1;395:1-10. doi: 10.1016/j.canlet.2017.02.028. Epub 2017 Mar 1.

PMID:
28259821
39.

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.

Le Pen J, Maillet L, Sarosiek K, Vuillier C, Gautier F, Montessuit S, Martinou JC, Letaï A, Braun F, Juin PP.

Cell Death Dis. 2017 Feb 9;8(2):e2596. doi: 10.1038/cddis.2016.127. No abstract available.

40.

Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.

Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS.

Leukemia. 2017 Oct;31(10):2075-2084. doi: 10.1038/leu.2017.32. Epub 2017 Jan 23.

41.

Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A.

Cancer Cell. 2017 Jan 9;31(1):142-156. doi: 10.1016/j.ccell.2016.11.011. Epub 2016 Dec 22.

42.

Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.

Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SWG, Gautier F, Juin PP.

Cell Rep. 2016 Dec 20;17(12):3347-3358. doi: 10.1016/j.celrep.2016.11.064.

43.

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA.

Cancer Discov. 2017 Feb;7(2):156-164. doi: 10.1158/2159-8290.CD-16-0999. Epub 2016 Dec 16.

44.

S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver.

Letai A.

Cancer Cell. 2016 Dec 12;30(6):834-835. doi: 10.1016/j.ccell.2016.11.016.

45.

Genomic evolution and chemoresistance in germ-cell tumours.

Taylor-Weiner A, Zack T, O'Donnell E, Guerriero JL, Bernard B, Reddy A, Han GC, AlDubayan S, Amin-Mansour A, Schumacher SE, Litchfield K, Turnbull C, Gabriel S, Beroukhim R, Getz G, Carter SL, Hirsch MS, Letai A, Sweeney C, Van Allen EM.

Nature. 2016 Nov 30;540(7631):114-118. doi: 10.1038/nature20596.

46.

Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.

Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, Fesik SW.

FEBS Lett. 2017 Jan;591(1):240-251. doi: 10.1002/1873-3468.12497. Epub 2016 Dec 19.

47.

To Prime, or Not to Prime: That Is the Question.

Potter DS, Letai A.

Cold Spring Harb Symp Quant Biol. 2016;81:131-140. doi: 10.1101/sqb.2016.81.030841. Epub 2016 Nov 3. Review.

PMID:
27811212
48.

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K.

Cancer Res. 2016 Nov 15;76(22):6495-6506. doi: 10.1158/0008-5472.CAN-16-1457. Epub 2016 Sep 26.

49.

Cristae remodeling causes acidification detected by integrated graphene sensor during mitochondrial outer membrane permeabilization.

Pham TD, Pham PQ, Li J, Letai AG, Wallace DC, Burke PJ.

Sci Rep. 2016 Oct 27;6:35907. doi: 10.1038/srep35907.

50.

Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia.

Bhola PD, Mar BG, Lindsley RC, Ryan JA, Hogdal LJ, Vo TT, DeAngelo DJ, Galinsky I, Ebert BL, Letai A.

J Clin Invest. 2016 Oct 3;126(10):3827-3836. doi: 10.1172/JCI82908. Epub 2016 Sep 6.

Supplemental Content

Support Center